|
medpundit |
||
 |
 |
|
Friday, July 02, 2004A cheap three-in-one generic AIDS pill from India is just as good as more expensive branded medicines and should be widely used in developing countries, researchers said Friday. Lack of scientific evidence about the clinical effectiveness of such generic fixed-dose combinations has until now caused some international AIDS donors to refuse to fund their use. But a team from the French national agency for AIDS research and Swiss charity Medecins sans Frontieres said Cipla's Triomune performed as well as brand drugs in the first open clinical study in a developing country. The study only lasted six months, but the generic pill made the HIV viral load undetectable in 80% of patients. The researchers say that that's the same sort of performance you see with the brand name drug. If so, that represents a tremendous savings potential, since the generic is $15 less a month than the brand name. The generic still hasn't been tested for safety, but if you're living with AIDS in a part of the world where clean drinking water is a challenge, a generic drug would certainly be better than nothing. posted by Sydney on 7/02/2004 07:54:00 AM 0 comments 0 Comments: |
|
